Leveling Up Supply Chain Initiatives To Ensure Accountability, Sustainability, And Optimization In IP Management

The contemporary landscape of clinical trials is undergoing exciting transformations. Presently, we have more opportunities than ever before, thanks to the exploration and introduction of novel biologics, cell and gene therapies into the clinical trial sphere. Additionally, recent technological innovations are available to alleviate the burden on both patients and trial sites, thereby facilitating patient participation and streamlining trial execution and the collection of dependable, high-quality data.

As we forge ahead in pioneering new therapeutic options and concurrently introduce cutting-edge technologies capable of gathering extensive and diverse data across all trial sites, the importance of a robust Interactive Response Technology (IRT) and drug accountability program cannot be overstated. Progress in cold chain management, direct-to-patient drug distribution, and other patient support solutions for clinical trials is reshaping conventional drug accountability and supply management programs.

Watch as the following industry experts explore the advancements in drug accountability facilitated through IRT:

• Maxime Schuchewytsch, Associate Director of Product Management Cenduit IRT, an IQVIA Business
• Jeremy Star, Product Manager Cenduit IRT, an IQVIA business
• Jon Walter, Associate Director, Business Operations and Capabilities Cenduit IRT, an IQVIA business
• Stefan Dürr, Senior Director of Client Delivery Cenduit IRT, an IQVIA business, Head of Drug Supply Center of Excellence

This discussion will encompass innovative methods for managing site variations and ensuring the establishment of an efficient and sustainable supply chain. Furthermore, speakers will delve into emerging technologies that harness the power of machine learning to revolutionize supply chain efficiency, capturing critical real-time factors vital for patient safety and adherence to protocol.